Bioterrorism Response Hampered by Profit

By Paul Kerstein

August 08, 2005CSO — In the last five years, the number of drugs, tools and vaccines available to combat bioterrorism has jumped from one to two because there was no money to be made. The Washington Post reports that despite promises from the drug industry and the passage of a $5.6 billion Project BioShield bill to speed development of products, the nation is hardly better off than it was in 2000. Senators are promoting legislation again that would grant incentives to companies to meet biodefense needs. However, one of the key incentives, extending patent protection for 18 additional months, has started sharp protests.  Opponents say the extension is a giveaway that would keep costs too high for too long, helping the pharmaceutical industry more than average Americans. Read more.

Read more about data protection in CSOonline's Data Protection section.

What is Tech Briefcase?
TechBriefcase is a new, free service where IT Professionals can Search, Store and Share IT white papers and content like this. Learn more
Bookmark content
Speed up your research efforts with content across the web.
Search and Store
Find the white papers you need. Create folders for any topic.
View Anywhere
Open your briefcase on your iPhone, tablet or desktop. Share with colleagues.
Don't have an account yet?
RESOURCE CENTER